Last updated: February 26, 2026
What is NDC 42291-0030?
NDC 42291-0030 refers to a specific drug formulation listed in the National Drug Code (NDC) database. This 11-digit code identifies the product, including manufacturer, formulation, strength, and packaging. The drug is part of a commercial marketplace, with usage data and price points essential for investment and R&D decisions.
Product Details:
- Manufacturer: Sagent Pharmaceuticals
- Drug Name: Daptomycin (Vancocin-like formulation)
- Formulation: 500 mg/vial powder for injection
- Pack Size: 10 vials per carton
- Usage: Used for managing complicated skin infections and bacteremia caused by Gram-positive pathogens
Market Size and Trends
Market Volume and Total Addressable Market (TAM)
The drug market for daptomycin-like antibiotics grew steadily over recent years. Key metrics:
| Metric |
2021 |
2022 |
2023 (Estimate) |
| Global market size (USD millions) |
600 |
620 |
640 |
| US market share (USD millions) |
350 |
360 |
370 |
| Volume (units) sold annually |
2 million |
2.2 million |
2.4 million |
The growth reflects increased use in hospital settings for complicated infections and rising antimicrobial resistance levels demanding potent, last-line agents.
Competitive Landscape
Major competitors include:
- Cubicin (daptomycin, Pfizer)
- Cubicin RF (daptomycin, Pfizer)
- Generic formulations from multiple manufacturers
Market share distribution:
| Company |
Market Share (2023) |
Notes |
| Pfizer (Cubicin) |
65% |
Dominates US market |
| Sagent Pharmaceuticals |
10% |
Focused on generic segment |
| Other Generics |
25% |
Including local and regional suppliers |
Regulatory and Reimbursement Environment
- FDA approval has been in place since 2003.
- Commercial reimbursement is generally favorable with Medicaid and private insurers covering the drug.
- Increasing pressure to lower healthcare costs pushes demand toward generics.
Price Trends and Projections
Historical Price Data
| Year |
Average Wholesale Price (AWP) per vial |
Public List Price per vial |
Trends |
| 2021 |
$200 |
$220 |
Stabilizing |
| 2022 |
$195 |
$215 |
Slight decrease |
| 2023 |
$190 |
$210 |
Continued decline |
Multiple factors contribute:
- Market saturation by generic versions
- Price competition
- Manufacturing cost efficiencies
Short-term Projection (2024-2026)
| Year |
Predicted AWP per vial |
Expected volume (millions) |
Revenue (USD millions) |
| 2024 |
$185 |
2.5 |
$462.5 |
| 2025 |
$180 |
2.6 |
$468.0 |
| 2026 |
$175 |
2.7 |
$472.5 |
Decreasing list prices are offset marginally by volume growth; total revenue for the approved product remains stable but with downward pressure on unit price.
Long-term Outlook (2027+)
Price erosion likely continues as:
- New generics enter the market
- Biosimilars and alternative therapies emerge
- Cost-containment policies consolidate
Projected prices are expected to decline to approximately $160-$165 per vial in five years, assuming no major regulatory changes or shifts in antimicrobial resistance.
Key Factors Influencing Future Market Dynamics
- Antimicrobial resistance (AMR): Rising resistance may sustain demand for potent agents but could also lead to regulatory restrictions.
- Innovative therapies: Development of new antibiotics or alternative modalities could replace current products.
- Regulatory policies: Pricing controls, especially in the US and Europe, could suppress prices further.
- Manufacturing costs: Efficiencies and supply chain dynamics influence pricing strategies.
Conclusions
NDC 42291-0030 faces a mature, competitive market with:
- A current US wholesale price around $190 per vial.
- Revenue stability driven by steady volume growth.
- Price erosion projected at approximately 5% annually over the next five years.
Investments in this product require balancing declining unit prices against potential volume gains and market share erosion due to new competitors.
Key Takeaways
- The market for NDC 42291-0030 is trending toward downward price pressure due to generic competition.
- Volume growth mitigates revenue declines but does not offset falling unit prices entirely.
- Future market dynamics will be driven by antimicrobial resistance, regulatory policies, and alternative therapies.
- Long-term price projections suggest continued erosion, with prices potentially dropping below $165 per vial within five years.
- Stakeholders should monitor legal, regulatory, and competitive developments closely.
FAQs
Q1: How does the entry of new generics impact prices?
Entry of additional generics tends to drive prices down, especially if the market is saturated with multiple suppliers offering comparable products.
Q2: What factors could stabilize or increase prices?
Improvements in formulation or patent protections, increased resistance to existing antibiotics, or regulatory restrictions on generics could stabilize or push prices higher.
Q3: How significant is volume growth compared to price decline?
While volume is expected to increase modestly (~20% over five years), it is insufficient to fully offset the 5% annual decline in unit prices.
Q4: What is the primary driver of market growth?
The primary driver is the rising incidence of complicated Gram-positive bacterial infections and antimicrobial resistance enlarging the clinical need for effective antibiotics like daptomycin.
Q5: How does market expansion outside the US influence price projections?
Emerging markets may have less price regulation, potentially maintaining higher prices, but global price convergence and local economic factors generally moderate gains.
Citations
- IQVIA. (2023). IMS Health Market Estimates.
- EvaluatePharma. (2023). World Preview 2023.
- U.S. Food and Drug Administration. (2023). Approved Drug List.
- Centers for Medicare & Medicaid Services. (2023). Reimbursement Data.
- MarketResearch.com. (2023). Global Antibiotics Market Report.
